Search results
Results from the WOW.Com Content Network
Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. [4] [5] It is not indicated for the preventive treatment of migraine. [6] Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist.
The BPCI Act is closely related to the Drug Price Competition and Patent Term Restoration Act of 1984 (or referred to as the "Hatch-Waxman Act"), which established abbreviated pathways for the approval of drug products under the Federal Food, Drug, and Cosmetic Act (FD&C Act). [1] [2]
The Quality Cancer Care Demonstration (QCCD) project was developed by community oncologists, with input from policy experts, to be a national Medicare demonstration project focused on ensuring the delivery of quality, cost-efficient medical care to patients with cancer, by reinforcing and expanding the use of evidence-based guidelines and the ...
The Drug Price Competition and Patent Term Restoration Act (Public Law 98-417), informally known as the Hatch-Waxman Act, is a 1984 United States federal law that established the modern system of generic drug regulation in the United States. The Act's two main goals are to facilitate entry of generic drugs into the market and to compensate the ...
An existing cancer drug has shown promise in halting Parkinson's disease progression in mouse models. More research is needed to confirm these findings. Could an FDA-approved cancer drug help stop ...
On Tuesday, Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted ...
The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The intent of the program is to allow covered entities to "stretch scarce federal resources as far as possible ...
The American Cancer Society estimates there will be more than 22,000 new esophageal cancer cases in the U.S. in 2024. ... -The U.S. Food and Drug Administration said it has approved BeiGene's drug ...